Previous 10 | Next 10 |
As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...
Merger activity moderated again last week with three new deals announced. The acquisition of Acorn International by First Ostia Port. The merger of DouYu International Holdings Limited and HUYA Inc. For further details see: Merger Arbitrage Mondays - 2 Potential Deals Co...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe earnings season heats up next week, with high-fliers Netflix (NASDAQ:NFLX), Tesla (NASDAQ:TSLA) and Chipotle (NYSE:CM...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are three worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB). The biotechnology industry has rightfully received a huge ...
The FDA has granted Orphan drug status to Immunomedics's ([[IMMU]] +0.3%) trodelvy (sacituzumab govitecan-hziy) for the treatment of adult and pediatric patients with glioblastoma.The orphan drug tag qualifies the Company for various development incentives, including tax credits, a waiver of ...
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products...
NEW YORK, NY / ACCESSWIRE / October 9, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Immunomedics, Inc. (NASDAQ: IMMU ) relating to the ...
In a series of recent articles, I have covered the top 50 stocks in the large-cap S&P 500, the mid-cap S&P 400, and the small-cap S&P 600. Those three indices cover 1500 stocks, but there are still more than 2200 listed U.S. companies not represented in those indices. ...
Merger activity increased last week with one new deal announced. The acquisition of Standard AVB Financial by Dollar Mutual Bancorp. InnerWorkings receives shareholder approval. For further details see: Merger Arbitrage Mondays - A Very Active Quarter Draws To A Clo...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences (NASDAQ: GILD) can be both a hero and a goat, depending on your perspective as an investor. The stock price rose from $17 in July 2010 to $118 in July 2015, as the company introduced revolutionary HIV drugs and helped bring a cure for hepatitis C to market. Since the...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are three worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB). The biotechnology industry has rightfully received a huge ...
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products...